Why Horizon Pharma Inc. Shares Soared Again

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company Horizon Pharma Inc.  (NASDAQ: HZNP  ) surged 32% today after acquiring the U.S. rights to arthritis treatment Vimovo from AstraZeneca (NYSE: AZN  ) for $35 million.

So what: AstraZeneca generated $5 million in Vimovo U.S. sales in the third quarter alone, so the acquisition certainly serves as a positive catalyst in Horizon's path to profitability. Of course, shares of Pozen (NASDAQ: ARLZ  ) , which originally licensed the drug to AstraZeneca in 2010, also soared on the news as it will be receiving a 10% royalty from Horizon as part of the deal.

Now what: Horizon management now expects to be profitable in 2014 on a non GAAP basis, with full-year revenue in the range of $190 million-$205 million.

"The acquisition of VIMOVO is a major step forward in our strategy to leverage our business model and maximize our commercial infrastructure and we expect it to create significant value for our shareholders," said Chairman and CEO Timothy Walbert. "We anticipate that this transaction will significantly increase our revenues and accelerate the Company to profitable operations."

So while the stock is certainly too hot and speculative for average investors, Horizon's newly bolstered growth prospects might be something for biotech-savvy Fools to look into.

More reliable ways to wealth
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2734889, ~/Articles/ArticleHandler.aspx, 10/1/2016 6:46:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:00 PM
HZNP $18.13 Up +0.36 +2.03%
Horizon Pharma CAPS Rating: **
ARLZ $4.85 Up +0.02 +0.41%
Aralez Pharmaceuti… CAPS Rating: **
AZN $32.86 Down -0.19 -0.57%
AstraZeneca CAPS Rating: ****